Compound reference

CJC-1295 Dosage Guide 2026: Clinical Trials vs Reported Use

By the Decadewise team Education only Last reviewed 19 July 2026 5 cited sources

Short answer

What it is: CJC-1295 is a long-acting GHRH analog that binds to albumin in the blood and keeps the pituitary releasing GH, raising IGF-1 with it.

The trial doses: the human studies dosed by bodyweight, 20 to 250 micrograms per kilogram across the arms, injected under the skin as single doses or in weekly to biweekly courses.

The headline number: one injection raised GH 2- to 10-fold for six days or more, with IGF-1 up 1.5- to 3-fold (Teichman, JCEM 2006).

The catch: the trials dosed micrograms per kilogram of the albumin-binding version. Forums mix micrograms, milligrams, and two versions, with and without DAC.

Why it trips people: doses are written in mcg or mg, syringes read in units, and the two only match once you know your vial's concentration.

The status: not FDA approved as of July 2026, and the human record is a handful of small 2006-era studies. Every trial figure here comes straight from the cited papers, DOIs at the bottom.

The calculator

How it works: type a vial size, a water amount, a syringe type, and a dose. It returns the concentration, the volume, and the units it reads as.

Units converter

Converts the numbers you type. It does not recommend a dose.

Vial amount mg Bacteriostatic water mL Syringe type Dose you want to convert mg

Concentration2.5 mg per mL

Volume to draw0.04 mL

Reads as4 units

Arithmetic only. Check the result against your own vial, your own reconstitution, and your own syringe before you trust any unit count.

On this page

Short answer Calculator Reported use What did the trials do? Trial dose vs internet dose How the units math works How many units is 100mcg? What's not known yet? The safety picture How this page is sourced The disclaimer

Community reports, not a protocol

What do people report running?

No personal log: I have not run this compound, so there is no field log of mine on this page. This section is what the community reports, not what I did.

The big split: everything reported online divides into two versions, with DAC and without DAC. The with-DAC version is the albumin-binding compound the trials studied; the without-DAC version, usually labeled Mod GRF 1-29, has no published human trials I could find.

What DAC users report: 1 to 2mg once or twice weekly, valued for fewer injections.

What no-DAC users report: 100 to 200mcg one to three times daily, usually paired with ipamorelin, often fasted or before bed.

The cycling posts: five days on and two off, or blocks of eight to twelve weeks, show up constantly. None of it comes from a trial.

The vials: 2mg and 5mg are the common sizes, sometimes blended 50/50 with ipamorelin in the same vial.

The mismatch: these are fixed amounts in micrograms or milligrams. The trials dosed micrograms per kilogram of bodyweight, so the two sets of numbers are not even in the same units.

Reports, not evidence: treat every number in this section as unverified community behavior, because that is exactly what it is.

Peer-reviewed trial data

What did the trials do?

The honest preamble: the human record is small. Two randomized, placebo-controlled, double-blind studies plus one pulsatility study, all from 2006, and a 120-participant phase 2 that was terminated early.

The setup: Teichman et al. (Journal of Clinical Endocrinology and Metabolism, 2006) ran two randomized, placebo-controlled, double-blind, ascending-dose studies in healthy adults aged 21 to 61, lasting 28 and 49 days.

The dosing: the first study gave one of four ascending single doses, injected under the skin. The second gave two or three doses, weekly or biweekly, all dosed by micrograms per kilogram of bodyweight.

The pulsatility study: Ionescu and Frohman (same journal, 2006) gave healthy men aged 20 to 40 a single injection of 60 or 90 mcg/kg, then sampled blood every 20 minutes overnight, before and one week after.

Study	Design	Dose	Duration
Teichman, study 1	single ascending dose, placebo-controlled	four dose levels, mcg/kg basis	28 days
Teichman, study 2	two or three doses, weekly or biweekly, placebo-controlled	mcg/kg basis	49 days
Ionescu and Frohman	single injection, overnight sampling	60 or 90 mcg/kg	1 week follow-up

The published human trial record for CJC-1295. Teichman et al. and Ionescu and Frohman, JCEM 2006.

The GH result: after one injection, mean GH rose 2- to 10-fold for six days or more, and mean IGF-1 rose 1.5- to 3-fold for 9 to 11 days (Teichman).

The half-life: estimated at 5.8 to 8.1 days, which is the whole point of the design. The compound binds to albumin in the blood, stretching its effect past the short half-life that limits natural GHRH.

The pulse finding: Ionescu and Frohman found trough GH up 7.5-fold and mean GH up 46%, with the pulse pattern preserved: pulse frequency and size unchanged.

The IGF-1 result: up 45% one week after a single injection, with no significant difference between the 60 and 90 mcg/kg doses.

The cumulative note: after multiple doses, IGF-1 stayed above baseline for up to 28 days (Teichman).

The supporting cast: a 2009 proteomics study (Sackmann-Sala et al.) tracked serum proteins in 11 healthy men one week after an injection, and the albumin-binding mechanism was demonstrated in animal work (Jetté et al., 2005).

Don't stretch this record: small studies, healthy volunteers, 49 days at the longest.

2 to 10x

GH rise lasting six days or more after one injection

1.5 to 3x

IGF-1 rise lasting 9 to 11 days

7.5x

trough GH one week after a single injection

5.8 to 8.1 d

estimated half-life, the point of the design

Teichman et al., JCEM 2006; Ionescu and Frohman, JCEM 2006.

Is the studied dose the same as the internet dose?

The usual dodge: most pages either duck the question or hand out a schedule with no trial behind it. We're doing neither.

What the trial's schedule is for

What it's for: the studies exist to answer research questions: does a long-acting GHRH analog raise GH and IGF-1, for how long, and does the pulse pattern survive. That is why dosing ran by micrograms per kilogram, in placebo-controlled arms.

What it is: early human pharmacology. Not a recommendation.

What people run online

What the posts show: fixed amounts, not bodyweight dosing, split between weekly with-DAC runs and multi-daily no-DAC runs paired with ipamorelin. The no-DAC version is not the molecule the trials studied.

The cost logic posted: a vial costs the same drawn slow or fast, and multi-daily schedules push injection frequency up. Reported schedules cluster around convenience, not around any published protocol.

None of those numbers is ours to hand you as an answer.

The real question: this is about your body, your risk tolerance, and a doctor who knows your history. What we can offer is the published record and the math behind a dose; the rest is for you and someone qualified to work out.

How does the units math work?

The point: the arithmetic, once, in general terms, with no dose attached to you.

Example one: say a 5mg vial gets reconstituted with 2mL of bacteriostatic water. That's 2.5mg per mL, or 2,500mcg per mL.

The syringe side: a U-100 insulin syringe carries 100 units per mL, so each unit equals 1/100th of a mL, which at this concentration is 25mcg, or 0.025mg. From there: 100mcg is 4 units, 1mg is 40 units, 2mg is 80 units.

Change one thing: take a 2mg vial reconstituted with 1mL instead. That's 2mg per mL, 2,000mcg per mL.

What changes: each unit now equals 20mcg instead of 25mcg. The same 100mcg is 5 units, not 4, and a full 2mg would read as 100 units, the entire barrel.

The forum trap: that "5 units" someone read on a forum could be 100mcg at one concentration and 125mcg at another.

Two common vial setups, on a U-100 syringe

Vial and water	Concentration	1 unit equals	What the article works out
5mg plus 2mL	2.5mg per mL (2,500mcg per mL)	25mcg (0.025mg)	100mcg is 4 units, 1mg is 40 units, 2mg is 80 units
2mg plus 1mL	2mg per mL (2,000mcg per mL)	20mcg	100mcg is 5 units, 2mg is 100 units

Syringe scale, before any concentration math

Syringe	Units per mL	1 unit equals
U-100	100 units per mL	0.01mL
U-40	40 units per mL	0.025mL

At the same unit mark, the U-40 pulls 2.5x the drug the U-100 does.

The other trap: the syringe, not the concentration. Insulin syringes read in units at two scales.

The two scales: U-100 packs 100 units per mL, so one unit is 0.01mL. U-40 packs 40 units per mL, so one unit is 0.025mL.

The 2.5x problem: draw on a U-40 with U-100 arithmetic in mind and every unit is 2.5x the volume you think it is. Same vial, same concentration, same mark on the barrel.

The mcg trap: this compound adds one the GLP-1 guides don't have. Trials and forums both write doses in micrograms, and 1mg is 1,000mcg, so mixing up the two is a thousandfold error on paper.

Read the syringe in your hand first, since everything downstream depends on its scale.

All three halves: that's the whole confusion: concentration, syringe scale, and micrograms versus milligrams. Trust the barrel, not its context: it knows neither your concentration nor its own scale. You know both.

How many units is 100mcg of CJC-1295?

The short answer: it depends on the concentration. At 2.5mg per mL (a 5mg vial plus 2mL of water), 100mcg reads as 4 units on a U-100 syringe. At 2mg per mL (a 2mg vial plus 1mL), 100mcg reads as 5 units.

The rule: no microgram or milligram amount converts to one universal units number. Concentration first, syringe type second, then the arithmetic, or run the calculator above.

What's not known yet?

The status: CJC-1295 is investigational. Not FDA approved as of July 2026, under any brand name.

What that means: the original development program stopped after the early studies, and no phase 3 trial was ever run. Nothing newer than the small 2006-era studies and a 2009 proteomics follow-up in 11 men has reached a peer-reviewed human readout.

The real gaps:

No published human data past 49 days of follow-up; Teichman dosed through day 14.
No published human trials at all for the without-DAC version that dominates the listings we've seen.
No verified data on stopping and restarting, or on years of sustained IGF-1 elevation.
No verified data on the community schedules: the daily no-DAC pulses have never been studied in a controlled trial, and the weekly with-DAC runs were studied only in Teichman's early work, at trial doses.

As of that check, anyone claiming otherwise is guessing.

The biggest gap: in our read, one gap matters more than any milligram or microgram figure. A research-grade vial has no independent verification behind what is in it, and the one illicitly made preparation analyzed in the literature was being sold before the trials finished (Henninge, Drug Test Anal 2010).

All taken on trust: identity, purity, sterility, and the labeled concentration itself.

The paper trail: when a doping-control lab analyzed an unknown preparation back in 2009, it found a peptide matching CJC-1295 and noted such peptides were already being made illicitly and sold before their trials finished (Henninge et al., 2010). The same paper flags CJC-1295 as a WADA-prohibited substance.

The quiet one: a mislabeled concentration breaks every calc above it. The math is only as reliable as the mg figure printed on the label.

The real worry: that is not a dosing question at all, a sourcing one, and it is the first thing we would lose sleep over.

How this page is sourced

No secondary summaries: every research figure above comes straight from the cited papers and trial records. Not lifted from a secondary summary.

The five sources: below, with their DOIs and PubMed IDs. Pull them yourself, and check what we claim against what they measured.

The standard: the full sourcing and citation-verification standard for the site lives on the methodology page. Any number here that needs correcting is corrected there first.

Last reviewed: 19 July 2026.

1
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID 16352683.
2
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. doi:10.1210/jc.2006-1702. PMID 17018654.
3
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. doi:10.1210/en.2004-0986. PMID 15817669.
4
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-7. doi:10.1016/j.ghir.2009.03.001. PMID 19386527.
5
Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-50. doi:10.1002/dta.233. PMID 21204297.

The disclaimer

Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice.

It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.